+ leukemia cells were transplanted into immune deficient NOD/SCID mice. These experiments showed that CD123 + cells were competent to establish and maintain leukemic populations in vivo. To begin to elucidate a biological role for CD123 in leukemia, primary AML samples were analyzed with respect to signal transduction activity in the MAPK, Akt, and Stat5 pathways. Phosphorylation was not detected in response to IL-3 stimulation, thereby suggesting CD123 is not active in conventional IL-3-mediated signaling. Collectively, these data indicate that CD123 represents a unique marker for primitive leukemic stem cells. Given the strong expression of this receptor on LSCs, we propose that targeting of CD123 may be a promising strategy for the preferential ablation of AML cells.
Introduction
Stem cells are commonly found in a variety of mammalian tissue systems. While the criteria by which such cells are defined vary depending upon the specific context, two properties are generally regarded as central features of stem cell populations: (1) true stem cells must exhibit some capacity for self-replication or self-renewal; and (2) stem cells must be capable of differentiating into the appropriate lineages. 1 Cells of this nature have been described for a number of tissues including hematopoietic, embryonic, neural, muscle and hepatic systems. [2] [3] [4] [5] [6] Thus, it is perhaps not surprising that similar cells have recently been documented in the context of malignant populations. [7] [8] [9] Indeed, a stem cell is in some respects the ideal target for malignant transformation in that relatively little biological change is required. Since stem cells already possess the genetic programming necessary to be highly proliferative and developmentally plastic, one can imagine that relatively subtle perturbations might be sufficient to induce disease.
One example of neoplasia arising from malignant stem cells has recently been documented in the hematopoietic system in the case of acute myelogenous leukemia (AML). This disease is characterized by premature arrest of myeloid development and the subsequent accumulation of large numbers of non-functional leukemic blasts. While leukemic blast cells are often of clonal origin and display relatively homogeneous features, it has been demonstrated that such populations are organized in a hierarchical fashion, analogous to normal hematopoietic progenitors. Thus, there is a phenotypically defined leukemic stem cell population that is sufficient to propagate leukemic blasts both in vitro and in vivo in xenogeneic mouse models of human AML. [7] [8] [9] [10] The concept of a leukemic stem cell (LSC) becomes critically important in considering the etiology of human disease. Clearly, in order to achieve durable remission, it will be necessary to specifically ablate the LSC population. However, previous studies, 11 as well as data from our group (CTJ, unpublished) suggests that LSCs are biologically distinct from more mature leukemic blasts and may not be responsive to conventional chemotherapeutic regimens. This observation is consistent with the clinical profile frequently seen for AML, wherein a majority of patients can achieve apparent complete remission, however, in most cases will relapse. 12, 13 If LSCs are more refractile to chemotherapy than blasts, it is attractive to propose that surviving stem cells are a major contributing factor to leukemic relapse. Thus, we suggest that strategies which specifically target LSCs may provide more effective treatment for AML patients.
In 1997, Bonnet and Dick described the phenotype for LSCs as CD34 7 Subsequent studies showed that LSCs are also CD34
− and fail to express Thy-1.
8,10
Although this phenotype is quite similar to that of normal primitive cells, we hypothesized that malignant transformation would yield changes in LSCs that would allow them to be distinguished from normal stem cells. One potential difference between normal and leukemic cells lies in their response to hematopoietic growth factors. Numerous studies have examined the cytokine response of primary leukemia cells and demonstrated mitogenic activity for IL-3, G-CSF, GM-CSF, SCF, FL, TPO and other factors. [14] [15] [16] Although these studies have focused on bulk populations of leukemia cells, one can imagine that differential sensitivity to cytokines may also exist at the level of primitive AML cells. Thus, as a means to address this issue, we examined the expression of growth factor receptors on AML blasts as well as on more primitive subsets of AML cells. The studies presented in this report demonstrate that the IL-3 receptor alpha chain (CD123) is highly expressed on leukemic but not normal CD34
− hematopoietic cells. We examine the biological relevance of this finding and suggest ways in which the phenomena may be of use for clinical application.
Materials and methods

Cell processing
Primary AML cells were obtained from the peripheral blood or bone marrow of patients at the Markey Cancer Center, Duke University Medical Center, and the University of Pennsylvania Medical Center. Normal bone marrow was obtained as waste material following pathological analysis, surgical marrow harvest, or from the National Disease Research Interchange (NDRI). All tissues were obtained with the approval of the respective Institutional Review Boards and appropriate informed consent. Marrow cells were depleted of erythrocytes by suspending in 150 mM NH 4 Cl + 10 mM NaHCO 3 for 5 min, followed by two washes with phosphate buffered saline (PBS). Blood cells were subjected to Ficoll-Paque (Pharmacia, Piscataway, NJ, USA) density gradient separation to isolate the mononuclear white blood cell compartment. Resulting leukocytes from marrow or blood were then used for immunoaffinity selection, and/or flow cytometric analysis or sorting. For CD34 + cell selection, the Miltenyi (Auburn, CA, USA) immunoaffinity device (varioMACS) was used according to the manufacturer's instructions. In some cases, leukocytes were cryopreserved at a concentration of 5 × 10 7 cells/ml in freezing medium consisting of Iscove's modified Dulbecco medium (IMDM), 40% fetal bovine serum (FBS) and 10% dimethylsulfoxide (DMSO).
Flow cytometry
Cytokine receptors were detected by labeling with the following monoclonal antibodies: CD114-biotin, CD116-FITC, CD123-PE, CD131-biotin (all from Pharmingen, San Diego, CA, USA), CD117-PE (Coulter, Miami, FL, USA), and CD135-PE (Caltag, Burlingame, CA, USA). Biotinylated antibodies were visualized by subsequent labeling with streptavidin-PE (SA-PE, Becton Dickinson, San Jose, CA, USA). Primitive AML subpopulations were identified using CD34-FITC or CD34-PE in combination with CD38-APC (Becton Dickinson). Primary AML cells were identified in NOD/SCID mice using CD45-PE (Pharmingen) specific to human cells. To monitor internalization of the CD123 antigen, cells were first labeled with CD123-biotin (Pharmingen) using standard conditions (on ice). Labeled cells were then washed to remove excess antibody and shifted to 37°C for 0, 30, 60, or 90 min. Finally, samples were returned to ice and labeled with SA-PE to detect antigen remaining on the cell surface. To analyze cells transplanted into NOD/SCID mice, bone marrow was harvested at 6-8 weeks post-transplantation. Cells were blocked with the anti-Fc receptor antibody 2.4G2 (Pharmingen) and 25% human serum, followed by double-labeling with human-specific CD34-FITC and CD45-PE antibodies. Control samples consisted of marrow cells from non-transplanted mice. In some cases, cells were also labeled with CD123-PE to ensure sustained expression of the CD123 antigen. For each specimen 50 000-100 000 events were analyzed. Using this approach, human cells could reliably be detected to a frequency as low as 0.1%. Any analysis falling below 0.1% positive cells was considered negative.
Immunoblots
Cell samples were lysed at a concentration of 2 × 10 7 cells/ml in PBS containing: 1% NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1 mM sodium vanadate (Na 3 VO 4 ), 30 l/ml aprotinin (Sigma), 1 mM phenylmethylsulfonyl fluoride (Sigma), 1 g/ml pepstatin, and 1 g/ml leupeptin (Oncogene Research, Cambridge, MA, USA); incubated on ice for 30 min, and centrifuged at 15 000 g for 10 min to remove debris. The resulting protein lysate was then aliquoted and stored at −80°C. For immunoblot analysis, protein lysates were thawed and mixed with sample buffer and reducing agent (Novex, San Diego, CA, USA, per manufacturer's instructions), and heated at 70°C for 10 min. Samples were then immediately analyzed by denaturing PAGE (Novex, 4-12% bis-tris or 7% tris-acetate gels) using the equivalent of 4 × 10 5 cells per lane. Following electrophoresis, samples were electro-transferred on to Immobilon-P membrane (Millipore, Bedford, MA, USA) and probed with the indicated antibodies. To detect CD123 (IL-3R alpha chain), antibodies S-12 (Santa Cruz Biotech, Santa Cruz, CA, USA) or 9F5 (Pharmingen) were used. For the analysis of Mek and Akt, protein-specific and phosphoprotein-specific rabbit polyclonal antibodies from New England Biolabs (Beverly, MA, USA) were used. Anti-Stat5 polyclonal (Transduction Labs, Lexington, KY, USA) and anti-phospho-Stat5 (New England Biolabs) were used to analyze the phosphorylation status of Stat5. All primary antibodies were detected using alkaline phosphataseconjugated secondary antibodies (Santa Cruz Biotechnology) and the ECF reagent (Pharmacia Biotech) per manufacturer's instructions. Blots were visualized using a Molecular Dynamics STORM 860 system and Imagequant Software.
NOD/SCID mouse assays
NOD/SCID mice (Jackson Laboratories, Bar Harbor, ME, USA) were exposed to 225 rads of ␥-irradiation from a 137 Cs source. Cells to be assayed were resuspended in 0.25 ml HBSS (Hanks balanced salt solution, Gibco, Rockville, MD, USA) with 2% FBS and injected i.v. into the tail vein. For the analysis of some sorted populations, 1 × 10 6 irradiated (2500 rads) mouse bone marrow cells were co-injected as carrier. After 6-8 weeks, animals were sacrificed and bone marrow was analyzed for the presence of human cells using flow cytometry (see above).
Results
Analysis of cytokine receptors demonstrates strong expression of CD123 on primitive leukemic, but not normal cells
To better understand the biology of primitive leukemia cells, we used multiparameter flow cytometry to analyze the expression of cytokine receptors previously implicated in the growth of malignant hematopoietic cells. While several receptors displayed interesting patterns of antibody labeling (a more detailed description of these studies will be presented elsewhere), the most striking feature observed was a remarkably high and well-conserved level of CD123 (IL-3R alpha chain) expression amongst primary AML specimens. Figure 1 shows representative examples of CD123 labeling in normal and leukemic tissue. In Figure 1a , total normal marrow, as well as more primitive subsets, are shown with respect to shows the same analysis for the primary AML specimen. M1 markers in the histograms indicate expression levels that are higher than 99% of isotype control samples. For each specimen, 50 000-100 000 events were analyzed. CD123 expression. Total marrow generally has about 7% positive cells for CD123, but only about 1% of the population expresses the antigen at high levels (see inset Figure 1a ). The CD34 + population of normal marrow also has readily evident CD123 expression (12% in Figure 1a , right histogram), as would be expected for a population known to contain hematopoietic progenitors. The labeling profile shown is in good agreement with previous studies by Sato et al that have also examined IL-3R␣ levels on human CD34 + cells. 17 However, the more primitive CD34
− compartment shows no significant expression of CD123 (Ͻ1%). In contrast, primary AML cells (Figure 1b ) displayed high levels of CD123. In both the overall CD34 + population, as well as the more primitive CD34
− compartment, greater than 99% of the cells were positive for CD123. Figure 2 shows five additional examples of CD123 labeling on CD34
− AML cells, further demonstrating the strong expression of this antigen on leukemic populations. Table 1 summarizes the experiments performed to date, and shows CD123 levels for primitive cells of AML subtypes M1, M2, and M4. Of the 18 primary AML specimens examined, CD123 was strongly expressed on the primitive leukemia cells in all but two instances. The two samples which had lower CD123 levels (samples AML-11 and AML-14, Table 1 ) both displayed a uniform shift in CD123 expression, but had an overall labeling intensity that was dimmer than most samples assayed. In many cases (nine of 18), CD123 negative cells were virtually undetectable (0% or less than 1%). Conversely, expression of CD123 was not detected on three of five normal samples of CD34
− cells and was barely detectable in two additional specimens (Ͻ1%).
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Figure 2
CD123 expression on five primitive AML populations. Five primary AML specimens were labeled with CD34, CD38, and CD123 and analyzed by flow cytometry. The figure shows CD123 labeling for the CD34
− gated populations from each sample. The dark sections indicate CD123 staining and the light sections indicate parallel labeling with an isotype control antibody. M1 markers in the histograms indicate expression levels that are higher than 99% of isotype control samples. For each specimen, 50 000-100 000 events were analyzed.
These flow cytometric analyses were confirmed using two different anti-CD123 monoclonal antibodies to ensure that the results were not an artifact caused by the use of a particular antibody.
The high level of CD123 expression found on all AML subtypes examined implies that IL-3R␣ might play a central role in creating or maintaining the leukemic state. To form the high affinity receptor for IL-3, both the ␣ and ␤ chains (CD123 and CD131 respectively) are necessary. Thus, expression of CD131 was also examined by flow cytometry on the AML specimens. Interestingly, while some expression was seen in bulk AML populations, in 15 of 15 specimens CD131 was never detected in the CD34 + compartment (data not shown).
In vivo engraftment properties of human CD123
+ leukemia cells in NOD/SCID mice
Given the strong CD123 expression observed on the vast majority of cells that phenotypically encompass the LSC population, it appeared likely that CD123 would be useful as a marker of LSCs. Therefore, to establish the functional capacity of CD123 + cells, transplantation studies using the NOD/SCID 
/CD123
+/− ) were also sorted and transplanted in parallel. The data in Figure 3 are a representative example of one specimen that showed strong engraftment of leukemic cells at 6 weeks postengraftment. Panel a shows total bone marrow cells labeled with antibodies specific to human CD34 and CD45. The flow cytometric profile clearly indicates that a large population of Table 2 summarizes the data for the three specimens tested. In all cases, the CD123 + cells were capable of engrafting the NOD/SCID animals. Moreover, in all but one instance, the CD123 − populations did not contribute to in vivo repopulation. Thus, as defined by the NOD/SCID model, we conclude that CD123 is expressed on the LSC.
Finally, as an independent means of confirming the leukemic origin of CD123 positive cells, we used flow cytometry to sort CD34
+ cells from two leukemic specimens. These samples were cultured for 4 days, synchronized and then harvested for cytogenetic analysis. Examination of spreads from each specimen showed that 20 out of 20 metaphases were positive for the leukemia-specific translocation.
Biological role of CD123 expression in leukemia cells
To further corroborate the data obtained by flow cytometry, immunoblot studies were performed to analyze IL-3R signal transduction components. For these studies, each AML sample was derived from a peripheral blood specimen and was sorted to isolate the CD34 + population, thus ensuring a virtually pure leukemic sample. First, expression of both the IL-3R ␣ and ␤ chains was examined. With respect to CD123, the data shown in Figure 4 
/CD38
− subset of normal cells ( Figure 1a and Table 1 ). Due to their low frequency, it was not possible to obtain sufficient CD34
− cells of either normal or AML origin for direct analysis by immunoblot. Nonetheless, detection of a clear signal in the overall CD34 + population corroborates the strong signal seen by flow cytometry for AML cells. Another point to note is that the molecular weight of the CD123 band appears to vary slightly between AML samples. We have performed RT-PCR fingerprint analyses of the same specimens and seen no obvious aberrancies (data not shown). Thus, it appears that varying degrees of post-translational modification are the most likely explanation for this observation. Consistent with the results obtained by flow cytometry, expression of CD131 was not detected (Figure 4, bottom panel) .
Despite the apparent absence of CD131, we reasoned that physiologically relevant levels of IL3-R ␤ chain might fall below the limits of sensitivity for flow cytometry or immunoblot assays. Also, the extremely high level of CD123, which alone is a low affinity IL-3 receptor, might be sufficient to induce a biological response. Thus, to begin exploring a potential functional role for CD123, we examined the response of primary AML cells to IL-3. Typically, stimulation of hematopoietic cells with IL-3 leads to several well-characterized intracellular signal transduction events. 18 Prevalent among these events are phosphorylation of Mek-1, Akt, and Stat-5. [19] [20] [21] [22] Consequently, immunoblot studies were performed on these proteins to assess the degree of phosphorylation, both in the presence or the absence of IL-3 stimulation. The data, shown in Figure 5 , show no detectable phosphorylation of Akt and Stat5 in the absence of IL-3, and only a moderate level of phosphorylation for Mek-1. Furthermore, in response to IL-3 stimulation, no appreciable increase in phosphorylation is seen for any of the proteins assayed. These results suggest that CD123 present on the surface of primary AML cells do not contribute significantly to signal transduction via conventional IL-3-mediated pathways.
Turnover of the CD123 antigen
Finally, we examined CD123 with respect to its use as a target for therapeutic intervention. Several recent studies have
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Figure 5
Phosphorylation of signal transduction components in response to IL-3. Three primary AML samples (lanes 1-3) were derived from peripheral blood and sorted to isolate the CD34 + population. Samples were treated with (+) or without (−) 20 ng/ml IL-3 for 15 min, then lysed and subjected to PAGE. Each gel was then electroblotted and membranes were probed with antibodies specific to either total or phosphorylated protein for Akt (a), Stat5 (b), and Mek-1 (c). The lane labeled C on each blot is an antibody control and is derived from NIH 3T3 cells treated ± 50 ng/ml PDGF (a and c), or TF-1 cells treated ± 25 ng/ml GM-SCF (b).
shown that monoclonal antibodies specific to tumor antigens can be useful therapeutic agents. 23, 24 In some cases the antibody alone can be used as a means to induce cell death via complement fixation or induction of apoptosis. 25 Alternatively, cytotoxic agents can be conjugated to an antibody such that they are delivered to antigen-expressing cells. 26, 27 An important consideration for this approach is whether or not the target antigen is internalized with any significant frequency after antibody binding. To examine this issue for CD123, and to explore the potential of CD123 for therapeutic intervention, AML cells were labeled with anti-CD123 antibody and incubated at 37°C for varying times. Samples were then shifted to 4°C and labeled with phycoerythrin conjugated secondary reagent to detect the remaining CD123 on the cell surface. A summary of these studies is shown for three primary AML specimens in Table 3 . While there was some variability in the rate of CD123 turnover between specimens, the mean reduction in CD123 levels after 60 min at 37°C was only 15% (±4%). Thus, turnover of the CD123 antigen appears to be relatively slow and suggests that targeting of CD123 with toxins requiring internalization may not be highly effective. Rather, it may be preferable to use anti-CD123 antibodies conjugated to radioisotopes such as 131 Iodine as a means to ablate CD123 positive cell populations.
Discussion
Several recent studies have suggested the presence and importance of stem cells in both the genesis and perpetuation of AML. Phenotypically, cells described as CD34
− or CD34 + /HLA-DR − appear to play a central role in the development of leukemic populations. 7, 8 Furthermore, there is evidence suggesting that such cells may be relatively resistant to chemotherapeutic drugs, and consequently contribute to the phenomenon of relapse. 11 Thus, a better understanding of LSC biology and the characterization of unique LSC antigens are essential to the development of better treatments for AML.
While the various AML subtypes display considerable diversity with respect to developmental characteristics, phenotype, cytokine responsiveness, etc, there appears to be a marked degree of functional conservation at the level of more primitive leukemic cells. This feature has been most clearly demonstrated by the work of Bonnet et al, 7 in which a CD34
− subpopulation was shown to be sufficient to establish leukemia in NOD/SCID mice. Similar studies by others have corroborated the existence of leukemic stem cells for both AML and CML and confirmed their relatively homogeneous phenotype and functional capacity. 8, 28 However, to date, no study has identified an antigenic feature of myeloid LSCs that may allow their identification or preferential targeting for ablative therapy. In this report, we have identified an additional commonality among CD34
− AML stem cells, expression of CD123, which facilitates their discrimination from normal hematopoietic stem cells. The conserved 29, 30 could result in up-regulation of the CD123 promoter.
While the CD123 antigen was readily detected at high levels on AML cells, the IL-3 receptor ␤ chain, CD131, was not detected. Thus, there is no reason to expect a priori that AML cells will transduce signal(s) from IL-3. Indeed, incubation of AML cells with IL-3 did not induce detectable phosphorylation of known intracellular signal transduction proteins. This observation appears to contradict previous studies that have indicated IL-3 promotes growth and survival of leukemic cells. [31] [32] [33] However, to our knowledge, there is no evidence to suggest that IL-3 is relevant to the in vivo behavior of AML cells. Further, there is no evidence that autocrine IL-3 activity is relevant to the biology of primitive AML cells, as has recently been demonstrated for CML. 34 Therefore, we suggest that IL-3 responsiveness in vitro may be a consequence of ex vivo culture and does not necessarily reflect intrinsic characteristics of AML cells in vivo.
Based on the findings in this report, as well as the studies of other investigators, it is unclear why CD123 is expressed on leukemic cells. One possible mechanism may be related to aberrant expression of transcription factors in leukemic cells. In seeking to further characterize this possibility, we noted that the transcription factor IRF-1 (interferon regulatory factor-1) was over-expressed in six of six primary AML specimens examined (data not shown, Guzman and Jordan, manuscript in preparation). Previous studies by Korpelainen et al 35 have shown that treatment of endothelial cells with IFN-␥ results in up-regulation of CD123. Similarly, our own studies have shown that treatment of primary AML cells with IFN-␥ increases expression of CD123 (data not shown). Thus, we speculate that aberrant expression of interferon regulatory molecules might play a role in controlling CD123 expression in AML cells. Future studies will address whether components of the interferon pathway are necessary and/or sufficient for CD123 expression in primary AML populations.
Regardless of its biological role, we suggest that the presence of CD123 on AML cells has several important ramifications. First, expression of this antigen formally demonstrates that LSCs are biologically distinct from their normal stem cell counterparts. While this feature is implied from the developmental behavior of leukemic blasts, it has never been shown to be a characteristic of primitive leukemia cells. Second, because CD123 is not readily found on normal hematopoietic stem cells, it provides a unique marker that can be used to identify malignant tissue. This feature may be useful for research purposes, as well as in minimal residual disease (MRD) studies. Further, the CD123 epitope represents a target to which therapeutic strategies may be directed. Previous clinical trials have used monoclonal antibodies against both the CD33 and CD45 antigens as a means to deliver radioisotopes to AML cells in vivo. 23 In addition, several other recent studies have shown exciting results using monoclonal antibodies specific to antigens on malignant cells such as CD20, CD52, and Her-2. 24, 36 We suggest that antibodies to CD123 may be useful in a similar paradigm and will be capable of delivering a cytotoxic hit that specifically targets the leukemic stem cell population. For this approach, the membrane turnover analysis performed in this study indicates that an isotope may be preferable to a toxin requiring intracellular localization.
In conclusion, we have shown that CD123 represents a unique antigenic marker for the identification of primitive leukemic cells from a broad range of human AML specimens. Our studies show that CD123 is generally expressed at high levels and may be indicative of previously uncharacterized aspects of AML biology. Future studies will seek to define the biological role of CD123 in human AML and to exploit the presence of this antigen as a means to target AML stem cells for destruction.
